First clinical trial with genetically modified malaria vaccine completed22 May 2020
In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)12 May 2020
In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.
Early symptoms in Radboudumc healthcare workers who were tested for SARS-CoV-212 May 2020
In Eurosurveillance RIHS researcher Alma Tostmann and colleagues from the Radboudumc COVID-19 Team describe that general symptoms like fever, headache, general malaise and muscle ache were associated with a positive SARS-CoV-2 test. Respiratory symptoms however, were not predictive for SARS-CoV-2.
A new treatment option for an antibiotic nightmare23 April 2020
Lung infections by Mycobacterium abscessus are emerging worldwide and are difficult to treat, because of the bacterium’s resistance. The group led by Jakko van Ingen discovered that inhalation of an old and normally toxic antibiotic may finally improve treatment outcomes of this severe infection.
Martin Boeree appointed as professor of Clinical Tuberculosis and other Mycobacterial Diseases23 April 2020
Martin Boeree is searching for shorter and better treatments for drug sensitive and resistant tuberculosis. He is also conducting interdisciplinary research on treatment and clinical relevance in the area of non-tuberculous mycobacteria.
Radboudumc researchers publish new insights into COVID-19 Consequences for treatment are now being examined internationally10 April 2020
Researchers at the Radboud university medical center seem to have found an essential mechanism in the disease process of Covid-19, which has so far been overlooked. If the insight is correct, it probably has important consequences for the treatment of the disease.
Stuttering DNA orchestrates the start of the mosquito’s life9 April 2020
A certain type of junk DNA that is found in mosquitoes and which repeats itself dozens of times, known as ‘satellite DNA’, has now been shown to play an essential role in the early development of mosquito embryos. Ronald van Rij and colleagues published their findings in Nature.
Dealing with COVID-19 in low- and middle-income countries26 March 2020
RIHS researcher Joost Hopman believes that low-and middle-income countries should intensify their preparedness for a possible COVID-19 outbreak. This was the core message of an opinion article that he wrote at the request of the medical journal JAMA.
Study into better protection for healthcare workers against coronavirus infection19 March 2020
Radboudumc and UMC Utrecht will investigate whether health care workers are better protected against the coronavirus after a vaccination against tuberculosis (BCG vaccine). This vaccine does not directly protect against the coronavirus, but provides a boost to the immune system.
The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV17 March 2020
In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations.
Interleukin-37 plays a rol in the pathogenesis and treatment of gout11 March 2020
RIMLS researchers Leo Joosten, Viola Klück and Rosanne van Deuren, in collaboration with the Dept. of Human Genetics, discovered that rare genetic variants in interleukin-37 link the anti-inflammatory cytokine to the pathogenesis and treatment of gout.
Citizen forum on coverage decisions in the Dutch health insurance benefit package3 February 2020
In this article published in Value in Health RIHS researchers Leon Bijlmakers, Maarten Jansen and Rob Baltussen describe the preferences and dilemmas expressed by Dutch citizens in eight case studies, all of which require trade-offs between criteria that cannot all be satisfied at the same time.
RIMLS PhD retreat registration is open23 January 2020
Yearly, RIMLS PhD candidates gather for the two-day PhD Retreat. Apart from the science, this event is highly valued for the opportunity to meet and get to know fellow PhD candidates during the social activities. Early bird registration and abstract submission deadline: 4 March 2020.
NWO Open Competition Domain Science - XS grant for Ronald van Rij and Jenny van der Wijst21 January 2020
NWO Domain Science has awarded Ronald van Rij, theme Infectious diseases and global health and Jennny van der Wijst, theme Renal disorders an XS grant. The XS category emphatically strives to encourage curiosity-driven and bold research involving a relatively quick analysis of a promising idea.
Resistance of malaria parasites against artemisinin explained7 January 2020
Malaria parasites that are resistant to the commonly used malaria medicine artemisinin are a growing problem. How these parasites become resistant has now been uncovered by the RIMLS group of Richard Bartfai, theme Infectious diseases and global health, and published in Science.
JPI-AMR grant for Quirijn de Mast and Marien de Jonge6 January 2020
The JPI-AMR grant ‘Diagnostics and surveillance of antimicrobial resistance: development of tools, technologies and methods for global use’ has been awarded to Quirijn de Mast and Marien de Jonge), the Charles University Prague and the Kilimanjaro Christian Medical Centre in Moshi, Tanzania.
Newly appointed Junior Principal Clinicians3 December 2019
The appointed junior Principal Clinician for RIMLS are Heidi Zweers-van Essen and Jenneke Leentjens. These caregivers are at the forefront of renewing patient care and take the lead in the development and realization of the Radboudumc vision.
Two RIHS researchers in top 1 percent by citations28 November 2019
Bart-Jan Kullberg and Jacques Meis, made it to this year’s list of highly cited researchers. Researchers in this list are selected for their exceptional research performance and are regarded to have had a major impact on fellow scientists.
Five RIMLS researchers in top 1 percent by citations26 November 2019
Leo Joosten, Jos van der Meer, Mihai Netea, Henk Stunnenberg and Frank van de Veerdonk, made it to this year’s list of highly cited researchers. Researchers in this list are selected for their exceptional research performance and are regarded to have had a major impact on fellow scientists.
RIMLS 25 years jubilee festival The Future is Yesterday3 October 2019
Together with more than 250 colleagues and alumni we celebrated 25 years of research into the molecular mechanisms of disease. During this exciting and informal event, we not only took a trip down memory lane, but also looked ahead to the next 25 years and beyond…...
Radboud-led collaboration generates innovative candidate drug against malaria19 September 2019
A molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria. The antimalarial properties were revealed thanks to one researcher’s inspired hunch when the psoriasis drug discovery programme came to a dead end.
Radboud study on Dirty Money wins Ig Nobel Prize17 September 2019
By shaking hands we are exchanging bacteria. Does this happen without direct hand-to-hand contact, for example when paying with paper money? Andreas Voss, clinical microbiologist at Radboudumc and CWZ, and colleagues in the United States received an Ig Nobel Prize for research into dirty money.
Four Veni grants for junior RIMLS researchers22 July 2019
Four junior researchers, affiliated to the RIMLS, have each received a Veni grant of 250,000 Euro from NWO. Our researchers received this prestigious grant for their remarkable and original talent and their ability to carry out innovative research.
4,8 million euros for prevention of tuberculosis among people with diabetes in Africa16 July 2019
Reinout van Crevel and Lindsey te Brake have received European funding of 4.8 million euros to lead an international consortium to screen thousands of people with diabetes in Uganda and Tanzania for TB, and investigate the effect and costs of 3 months preventive treatment for TB.
Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies18 June 2019
Exome sequencing may provide a genetic diagnosis in a significant number of patients in a single genetic test. Alexander Hoischen and Mihai Netea, theme Infectious diseases and global health, and colleagues, published their results in Genome Medicine.
Developing malaria gametocytes under attack6 June 2019
In Science Translational Medicine, researchers from the group of Teun Bousema and international colleagues have revealed previously unknown targets of natural human antibody responses that are found on the surfaces of red blood cells infected with malaria parasites.
The XN-30 hematology analyzer for rapid sensitive detection of malaria a diagnostic accuracy study6 June 2019
In BMC Medicine Annelies Post, Berenger Kaboré, Isaie Reuling and colleagues described a new method of malaria detection using whole blood: the XN-30 is a new hematology analyzer which simultaneously provides a complete blood count and quantification of malaria parasitemia, allowing rapid treatment.
Three VIDI grants for RIMLS researchers24 May 2019
Matthijs Jore, Daniele Tauriello and Johannes Textor are each to receive up to 800,000 euros to develop an innovative research theme and to build up their own research group. NWO is awarding the Vidi grant as part of the Innovational Research Incentives Scheme.
Minocycline to treat pulmonary Mycobacterium avium complex disease9 May 2019
In Journal of Antimicrobial Chemotherapy Mike Ruth, Jakko van Ingen and colleagues showed that minocycline may be useful to treat pulmonary diseases caused by Mycobacterium avium complex bacteria. This is important as few drugs are active against this disease and treatment outcomes are very poor.
Removal of sialic acid from platelets responsible for thrombocytopenia in dengue23 April 2019
In the PLoS Pathogens Quirijn de Mast and his colleagues showed that excessive binding of the coagulation protein von Willebrand factor leads to removal of sialic acid from platelets and platelet clearance.